Potassium Channel Blockers

"Potassium Channel Blockers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A class of drugs that act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of ACTION POTENTIALS. They are used as ANTI-ARRHYTHMIA AGENTS and VASODILATOR AGENTS.

Descriptor ID	D026902
MeSH Number(s)	D27.505.519.562.500 D27.505.954.411.645
Concept/Terms	Potassium Channel Blockers Potassium Channel Blockers Blockers, Potassium Channel Channel Blockers, Potassium

Below are MeSH descriptors whose meaning is more general than "Potassium Channel Blockers".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Membrane Transport Modulators [D27.505.519.562]
Potassium Channel Blockers [D27.505.519.562.500]
Therapeutic Uses [D27.505.954]
Cardiovascular Agents [D27.505.954.411]
Potassium Channel Blockers [D27.505.954.411.645]

Below are MeSH descriptors whose meaning is more specific than "Potassium Channel Blockers".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Potassium Channel Blockers" by people in this website by year, and whether "Potassium Channel Blockers" was a major or minor topic of these publications.

Bar chart showing 29 publications over 18 distinct years, with a maximum of 3 publications in 2000 and 2002 and 2012

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	0	1	1
1999	0	2	2
2000	1	2	3
2001	1	0	1
2002	2	1	3
2003	2	0	2
2004	0	1	1
2005	0	1	1
2006	2	0	2
2008	1	0	1
2009	0	1	1
2010	0	1	1
2011	0	2	2
2012	1	2	3
2015	1	0	1
2016	1	0	1
2019	1	1	2
2020	0	1	1

Below are the most recent publications written about "Potassium Channel Blockers" by people in Profiles.

Burashnikov A, Barajas-Martinez H, Hu D, Robinson VM, Grunnet M, Antzelevitch C. The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity. J Cardiovasc Pharmacol. 2020 08; 76(2):164-172.

View in: PubMed
Stabenau HF, Shen C, Tereshchenko LG, Waks JW. Changes in global electrical heterogeneity associated with dofetilide, quinidine, ranolazine, and verapamil. Heart Rhythm. 2020 03; 17(3):460-467.

View in: PubMed
Camm AJ, Dorian P, Hohnloser SH, Kowey PR, Tyl B, Ni Y, Vandzhura V, Maison-Blanche P, de Melis M, Sanders P. A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation. Eur Heart J Cardiovasc Pharmacother. 2019 01 01; 5(1):21-28.

View in: PubMed
Chan KY, Chang RS, Lau VW, Chan ML, Lai T. Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine. Ann Palliat Med. 2016 Oct; 5(4):311-314.

View in: PubMed
Robinson VM, Kowey PR. Smoothing the Bumpy Road to Antiarrhythmic Drug Development. Circulation. 2015 Dec 08; 132(23):2195-7.

View in: PubMed
Pavri BB, Greenberg HE, Kraft WK, Lazarus N, Lynch JJ, Salata JJ, Bilodeau MT, Regan CP, Stump G, Fan L, Mehta A, Wagner JA, Gutstein DE, Bloomfield D. MK-0448, a specific Kv1.5 inhibitor: safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans. Circ Arrhythm Electrophysiol. 2012 Dec; 5(6):1193-201.

View in: PubMed
Doss MX, Di Diego JM, Goodrow RJ, Wu Y, Cordeiro JM, Nesterenko VV, Barajas-Mart?nez H, Hu D, Urrutia J, Desai M, Treat JA, Sachinidis A, Antzelevitch C. Maximum diastolic potential of human induced pluripotent stem cell-derived cardiomyocytes depends critically on I(Kr). PLoS One. 2012; 7(7):e40288.

View in: PubMed
Burashnikov A, Barajas-Martinez H, Hu D, Nof E, Blazek J, Antzelevitch C. Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity. J Cardiovasc Pharmacol. 2012 Jun; 59(6):539-46.

View in: PubMed
Tabak J, Tomaiuolo M, Gonzalez-Iglesias AE, Milescu LS, Bertram R. Fast-activating voltage- and calcium-dependent potassium (BK) conductance promotes bursting in pituitary cells: a dynamic clamp study. J Neurosci. 2011 Nov 16; 31(46):16855-63.

View in: PubMed
Minoura Y, Di Diego JM, Barajas-Mart?nez H, Zygmunt AC, Hu D, Sicouri S, Antzelevitch C. Ionic and cellular mechanisms underlying the development of acquired Brugada syndrome in patients treated with antidepressants. J Cardiovasc Electrophysiol. 2012 Apr; 23(4):423-32.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement